Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DE3 is a high-potency omega-3 dietary supplement developed by LYS PHARMA in partnership with the U.S.-based company PRN (Physician Recommended Nutriceuticals). Specifically formulated for the management of dry eye disease, DE3 contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a re-esterified triglyceride (rTG) form. This formulation is designed to enhance absorption and bioavailability compared to standard ethyl ester omega-3 products. DE3 works by modulating the inflammatory response on the ocular surface and improving the quality of the lipid layer of the tear film. Its efficacy is supported by clinical data, including double-blind, placebo-controlled trials (DBDCT), which demonstrate improvements in tear osmolarity and symptomatic relief for patients with dry eyes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DE3.